Intermediate Capital Group
Intermediate Capital Group plc, established in 1989, is a global investment firm specializing in private debt, credit, and equity investments. It focuses on middle-market companies, providing financing solutions across the capital structure, including growth capital, acquisition finance, and real estate debt. The firm invests in various sectors, with a preference for insurance, healthcare, education, and commercial real estate in the United Kingdom. It operates in North America, Europe, and Asia Pacific, with offices across these regions. Intermediate Capital Group manages assets from third-party investors and its balance sheet, totaling €12.1 billion. It is one of the largest independent mezzanine providers globally, known for its long track record in European senior loans and high yield bonds. The firm structures its investments as subordinated loans with equity warrants, preferred equity, and other debt instruments, typically with maturities of seven to ten years. It seeks minority and majority stakes in companies and aims to build genuine partnerships with management teams.
F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.